search
Back to results

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2)

Primary Purpose

Hypertension

Status
Active
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Olmesartan
Amlodipine
Indapamide
Placebo
Zilebesiran
Sponsored by
Alnylam Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring High blood pressure, Hypertension, Hypertensive, siRNA, Angiotensinogen, AGT

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Office SBP at Screening as follows:

    1. ≥155 mmHg and ≤180 mmHg for patients with untreated hypertension
    2. ≥145 mmHg and ≤180 mmHg for patients on antihypertensive medications
  • 24-hour mean SBP >130 mmHg and ≤160 mmHg by ABPM after at least 4 weeks of run-in

Exclusion Criteria:

  • Secondary hypertension, orthostatic hypotension
  • Elevated potassium >5 mEq/L
  • Estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73m^2
  • Received an investigational agent within the last 30 days
  • Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, newly diagnosed Type 2 diabetes mellitus
  • History of any cardiovascular event within 6 months prior to randomization
  • History of intolerance to SC injection(s)

Sites / Locations

  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trials Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trials Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trials Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Placebo Comparator

Placebo Comparator

Arm Label

Zilebesiran (Add-on to Olmesartan)

Placebo (Add-on to Olmesartan)

Zilebesiran (Add-on to Amlodipine)

Placebo (Add-on to Amlodipine)

Zilebesiran (Add-on to Indapamide)

Placebo (Add-on to Indapamide)

Arm Description

Following a run-in on olmesartan, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to olmesartan. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.

Following a run-in on olmesartan, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to olmesartan. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.

Following a run-in on amlodipine, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to amlodipine. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.

Following a run-in on amlodipine, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to amlodipine. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.

Following a run-in on indapamide, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to indapamide. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.

Following a run-in on indapamide, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to indapamide. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.

Outcomes

Primary Outcome Measures

Change from Baseline at Month 3 in 24-Hour Mean Systolic Blood Pressure (SBP) Assessed by Ambulatory Blood Pressure Monitoring (ABPM)

Secondary Outcome Measures

Change from Baseline at Month 3 in Office SBP
Time-adjusted Change from Baseline through Month 6 in Office SBP 24-hour Mean SBP, Assessed by ABPM
Proportion of Patients with 24-hour Mean SBP Assessed by ABPM <130 mmHg and/or Reduction from Baseline ≥ 20 mmHg without Escape Antihypertensive Medication at Month 6
Change in 24-hour Mean SBP and DBP, Assessed by ABPM
Change in Office SBP and DBP
Change in Daytime and Nighttime Mean SBP and DBP, Assessed by ABPM
Daytime is defined as 6 am to 9:59 pm and nighttime is defined as 10 pm to 5:59 am.
Change from Baseline in Serum Angiotensinogen (AGT)

Full Information

First Posted
October 22, 2021
Last Updated
September 15, 2023
Sponsor
Alnylam Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT05103332
Brief Title
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
Acronym
KARDIA-2
Official Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 5, 2021 (Actual)
Primary Completion Date
September 18, 2023 (Anticipated)
Study Completion Date
December 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alnylam Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
High blood pressure, Hypertension, Hypertensive, siRNA, Angiotensinogen, AGT

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
672 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Zilebesiran (Add-on to Olmesartan)
Arm Type
Experimental
Arm Description
Following a run-in on olmesartan, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to olmesartan. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
Arm Title
Placebo (Add-on to Olmesartan)
Arm Type
Experimental
Arm Description
Following a run-in on olmesartan, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to olmesartan. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
Arm Title
Zilebesiran (Add-on to Amlodipine)
Arm Type
Experimental
Arm Description
Following a run-in on amlodipine, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to amlodipine. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
Arm Title
Placebo (Add-on to Amlodipine)
Arm Type
Placebo Comparator
Arm Description
Following a run-in on amlodipine, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to amlodipine. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
Arm Title
Zilebesiran (Add-on to Indapamide)
Arm Type
Placebo Comparator
Arm Description
Following a run-in on indapamide, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to indapamide. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
Arm Title
Placebo (Add-on to Indapamide)
Arm Type
Placebo Comparator
Arm Description
Following a run-in on indapamide, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to indapamide. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
Intervention Type
Drug
Intervention Name(s)
Olmesartan
Intervention Description
Olmesartan administered orally
Intervention Type
Drug
Intervention Name(s)
Amlodipine
Intervention Description
Amlodipine administered orally
Intervention Type
Drug
Intervention Name(s)
Indapamide
Intervention Description
Indapamide administered orally
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo administered by subcutaneous (SC) injection
Intervention Type
Drug
Intervention Name(s)
Zilebesiran
Other Intervention Name(s)
ALN-AGT01
Intervention Description
Zilebesiran administered by SC injection
Primary Outcome Measure Information:
Title
Change from Baseline at Month 3 in 24-Hour Mean Systolic Blood Pressure (SBP) Assessed by Ambulatory Blood Pressure Monitoring (ABPM)
Time Frame
Baseline and Month 3
Secondary Outcome Measure Information:
Title
Change from Baseline at Month 3 in Office SBP
Time Frame
Baseline and Month 3
Title
Time-adjusted Change from Baseline through Month 6 in Office SBP 24-hour Mean SBP, Assessed by ABPM
Time Frame
Baseline through Month 6
Title
Proportion of Patients with 24-hour Mean SBP Assessed by ABPM <130 mmHg and/or Reduction from Baseline ≥ 20 mmHg without Escape Antihypertensive Medication at Month 6
Time Frame
Baseline and Month 6
Title
Change in 24-hour Mean SBP and DBP, Assessed by ABPM
Time Frame
Baseline and Month 6
Title
Change in Office SBP and DBP
Time Frame
Baseline and Month 6
Title
Change in Daytime and Nighttime Mean SBP and DBP, Assessed by ABPM
Description
Daytime is defined as 6 am to 9:59 pm and nighttime is defined as 10 pm to 5:59 am.
Time Frame
Baseline and Month 6
Title
Change from Baseline in Serum Angiotensinogen (AGT)
Time Frame
Baseline through Month 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Office SBP at Screening as follows: ≥155 mmHg and ≤180 mmHg for patients with untreated hypertension ≥145 mmHg and ≤180 mmHg for patients on antihypertensive medications 24-hour mean SBP >130 mmHg and ≤160 mmHg by ABPM after at least 4 weeks of run-in Exclusion Criteria: Secondary hypertension, orthostatic hypotension Elevated potassium >5 mEq/L Estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73m^2 Received an investigational agent within the last 30 days Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, newly diagnosed Type 2 diabetes mellitus History of any cardiovascular event within 6 months prior to randomization History of intolerance to SC injection(s)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Alnylam Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Clinical Trial Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35211
Country
United States
Facility Name
Clinical Trial Site
City
Mesa
State/Province
Arizona
ZIP/Postal Code
85213
Country
United States
Facility Name
Clinical Trial Site
City
Tempe
State/Province
Arizona
ZIP/Postal Code
85281
Country
United States
Facility Name
Clinical Trial Site
City
Tempe
State/Province
Arizona
ZIP/Postal Code
85282
Country
United States
Facility Name
Clinical Trial Site
City
Bakersfield
State/Province
California
ZIP/Postal Code
93309
Country
United States
Facility Name
Clinical Trial Site
City
Bell Gardens
State/Province
California
ZIP/Postal Code
90201
Country
United States
Facility Name
Clinical Trials Site
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90211
Country
United States
Facility Name
Clinical Trial Site
City
Canoga Park
State/Province
California
ZIP/Postal Code
91304
Country
United States
Facility Name
Clinical Trial Site
City
Carlsbad
State/Province
California
ZIP/Postal Code
92008
Country
United States
Facility Name
Clinical Trial Site
City
Encinitas
State/Province
California
ZIP/Postal Code
92024
Country
United States
Facility Name
Clinical Trial Site
City
Garden Grove
State/Province
California
ZIP/Postal Code
92844
Country
United States
Facility Name
Clinical Trial Site
City
Hollywood
State/Province
California
ZIP/Postal Code
91606
Country
United States
Facility Name
Clinical Trial Site
City
Huntington Beach
State/Province
California
ZIP/Postal Code
92647
Country
United States
Facility Name
Clinical Trial Site
City
Irvine
State/Province
California
ZIP/Postal Code
92614
Country
United States
Facility Name
Clinical Trial Site
City
Long Beach
State/Province
California
ZIP/Postal Code
90805
Country
United States
Facility Name
Clinical Trial Site
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
Clinical Trial Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Clinical Trial Site
City
Mission Hills
State/Province
California
ZIP/Postal Code
91345
Country
United States
Facility Name
Clinical Trial Site
City
Oceanside
State/Province
California
ZIP/Postal Code
92056
Country
United States
Facility Name
Clinical Trial Site
City
Panorama City
State/Province
California
ZIP/Postal Code
91402
Country
United States
Facility Name
Clinical Trial Site
City
Pomona
State/Province
California
ZIP/Postal Code
91767
Country
United States
Facility Name
Clinical Trial Site
City
Pomona
State/Province
California
ZIP/Postal Code
91768
Country
United States
Facility Name
Clinical Trial Site
City
S. Gate
State/Province
California
ZIP/Postal Code
90280
Country
United States
Facility Name
Clinical Trial Site
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Facility Name
Clinical Trial Site
City
Tustin
State/Province
California
ZIP/Postal Code
92780
Country
United States
Facility Name
Clinical Trial Site
City
Upland
State/Province
California
ZIP/Postal Code
91786
Country
United States
Facility Name
Clinical Trial Site
City
Valencia
State/Province
California
ZIP/Postal Code
91355
Country
United States
Facility Name
Clinical Trial Site
City
Victorville
State/Province
California
ZIP/Postal Code
92395
Country
United States
Facility Name
Clinical Trial Site
City
Vista
State/Province
California
ZIP/Postal Code
92083
Country
United States
Facility Name
Clinical Trial Site
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20011
Country
United States
Facility Name
Clinical Trial Site
City
Bradenton
State/Province
Florida
ZIP/Postal Code
34208
Country
United States
Facility Name
Clinical Trial Site
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33756
Country
United States
Facility Name
Clinical Trial Site
City
Coconut Creek
State/Province
Florida
ZIP/Postal Code
33073
Country
United States
Facility Name
Clinical Trial Site
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134
Country
United States
Facility Name
Clinical Trial Site
City
Hallandale Beach
State/Province
Florida
ZIP/Postal Code
33009
Country
United States
Facility Name
Clinical Trial Site
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
Facility Name
Clinical Trial Site
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
Facility Name
Clinical Trial Site
City
Inverness
State/Province
Florida
ZIP/Postal Code
34452
Country
United States
Facility Name
Clinical Trial Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32204
Country
United States
Facility Name
Clinical Trial Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
Facility Name
Clinical Trial Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32256
Country
United States
Facility Name
Clinical Trial Site
City
Lake City
State/Province
Florida
ZIP/Postal Code
32055
Country
United States
Facility Name
Clinical Trials Site
City
Margate
State/Province
Florida
ZIP/Postal Code
33063
Country
United States
Facility Name
Clinical Trial Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33032
Country
United States
Facility Name
Clinical Trial Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33125
Country
United States
Facility Name
Clinical Trial Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33135
Country
United States
Facility Name
Clinical Trial Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33144
Country
United States
Facility Name
Clinical Trial Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33165
Country
United States
Facility Name
Clinical Trial Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Facility Name
Clinical Trial Site
City
Naples
State/Province
Florida
ZIP/Postal Code
34105
Country
United States
Facility Name
Clinical Trial Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32162
Country
United States
Facility Name
Clinical Trial Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32801
Country
United States
Facility Name
Clinical Trial Site
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33027
Country
United States
Facility Name
Clinical Trial Site
City
Saint Augustine
State/Province
Florida
ZIP/Postal Code
32086
Country
United States
Facility Name
Clinical Trial Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33603
Country
United States
Facility Name
Clinical Trial Site
City
Winter Haven
State/Province
Florida
ZIP/Postal Code
33880
Country
United States
Facility Name
Clinical Trial Site
City
Winter Park
State/Province
Florida
ZIP/Postal Code
32789
Country
United States
Facility Name
Clinical Trial Site
City
Acworth
State/Province
Georgia
ZIP/Postal Code
30101
Country
United States
Facility Name
Clinical Trial Site
City
Canton
State/Province
Georgia
ZIP/Postal Code
30114
Country
United States
Facility Name
Clinical Trial Site
City
Columbus
State/Province
Georgia
ZIP/Postal Code
31904
Country
United States
Facility Name
Clinical Trial Site
City
Eatonton
State/Province
Georgia
ZIP/Postal Code
31024
Country
United States
Facility Name
Clinical Trial Site
City
Macon
State/Province
Georgia
ZIP/Postal Code
31210
Country
United States
Facility Name
Clinical Trial Site
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31406
Country
United States
Facility Name
Clinical Trial Site
City
Berwyn
State/Province
Illinois
ZIP/Postal Code
60402
Country
United States
Facility Name
Clinical Trial Site
City
Valparaiso
State/Province
Indiana
ZIP/Postal Code
46383
Country
United States
Facility Name
Clinical Trial Site
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
Clinical Trial Site
City
Bossier City
State/Province
Louisiana
ZIP/Postal Code
71111
Country
United States
Facility Name
Clinical Trial Site
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70769
Country
United States
Facility Name
Clinical Trial Site
City
Prairieville
State/Province
Louisiana
ZIP/Postal Code
70769
Country
United States
Facility Name
Clinical Trial Site
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71105
Country
United States
Facility Name
Clinical Trial Site
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21229
Country
United States
Facility Name
Clinical Trial Site
City
Southgate
State/Province
Michigan
ZIP/Postal Code
48195
Country
United States
Facility Name
Clinical Trial Site
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39209
Country
United States
Facility Name
Clinical Trial Site
City
Hazelwood
State/Province
Missouri
ZIP/Postal Code
63042
Country
United States
Facility Name
Clinical Trial Site
City
Jefferson City
State/Province
Missouri
ZIP/Postal Code
65109
Country
United States
Facility Name
Clinical Trial Site
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63106
Country
United States
Facility Name
Clinical Trial Site
City
Henderson
State/Province
Nevada
ZIP/Postal Code
89052
Country
United States
Facility Name
Clinical Trial Site
City
Bronx
State/Province
New York
ZIP/Postal Code
10456
Country
United States
Facility Name
Clinical Trial Site
City
New York
State/Province
New York
ZIP/Postal Code
10036
Country
United States
Facility Name
Clinical Trial Site
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Clinical Trial Site
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27403
Country
United States
Facility Name
Clinical Trial Site
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27410
Country
United States
Facility Name
Clinical Trial Site
City
Greenville
State/Province
North Carolina
ZIP/Postal Code
27834
Country
United States
Facility Name
Clinical Trial Site
City
Monroe
State/Province
North Carolina
ZIP/Postal Code
28112
Country
United States
Facility Name
Clinical Trial Site
City
Marion
State/Province
Ohio
ZIP/Postal Code
43302
Country
United States
Facility Name
Clinical Trial Site
City
Norman
State/Province
Oklahoma
ZIP/Postal Code
73072
Country
United States
Facility Name
Clinical Trial Site
City
Medford
State/Province
Oregon
ZIP/Postal Code
97504
Country
United States
Facility Name
Clinical Trial Site
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29607
Country
United States
Facility Name
Clinical Trial Site
City
Little River
State/Province
South Carolina
ZIP/Postal Code
29566
Country
United States
Facility Name
Clinical Trial Site
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38119
Country
United States
Facility Name
Clinical Trial Site
City
Amarillo
State/Province
Texas
ZIP/Postal Code
79109
Country
United States
Facility Name
Clinical Trial Site
City
Carrollton
State/Province
Texas
ZIP/Postal Code
75010
Country
United States
Facility Name
Clinical Trial Site
City
Coppell
State/Province
Texas
ZIP/Postal Code
75019
Country
United States
Facility Name
Clinical Trial Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75251
Country
United States
Facility Name
Clinical Trial Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77074
Country
United States
Facility Name
Clinical Trial Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77081
Country
United States
Facility Name
Clinical Trial Site
City
Lake Jackson
State/Province
Texas
ZIP/Postal Code
77566
Country
United States
Facility Name
Clinical Trial Site
City
Plano
State/Province
Texas
ZIP/Postal Code
75093
Country
United States
Facility Name
Clinical Trial Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Clinical Trial Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78240
Country
United States
Facility Name
Clinical Trial Site
City
Sherman
State/Province
Texas
ZIP/Postal Code
75092
Country
United States
Facility Name
Clinical Trial Site
City
Splendora
State/Province
Texas
ZIP/Postal Code
77372
Country
United States
Facility Name
Clinical Trial Site
City
Stephenville
State/Province
Texas
ZIP/Postal Code
76401
Country
United States
Facility Name
Clinical Trial Site
City
Sugar Land
State/Province
Texas
ZIP/Postal Code
77479
Country
United States
Facility Name
Clinical Trial Site
City
Tomball
State/Province
Texas
ZIP/Postal Code
77375
Country
United States
Facility Name
Clinical Trial Site
City
Waco
State/Province
Texas
ZIP/Postal Code
76708
Country
United States
Facility Name
Clinical Trials Site
City
Wichita Falls
State/Province
Texas
ZIP/Postal Code
76309
Country
United States
Facility Name
Clinical Trial Site
City
Burke
State/Province
Virginia
ZIP/Postal Code
22015
Country
United States
Facility Name
Clinical Trial Site
City
Kenosha
State/Province
Wisconsin
ZIP/Postal Code
53142
Country
United States
Facility Name
Clinical Trial Site
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
Clinical Trial Site
City
Brampton
State/Province
Ontario
Country
Canada
Facility Name
Clinical Trial Site
City
Burlington
State/Province
Ontario
Country
Canada
Facility Name
Clinical Trial Site
City
Concord
State/Province
Ontario
Country
Canada
Facility Name
Clinical Trial Site
City
Etobicoke
State/Province
Ontario
Country
Canada
Facility Name
Clinical Trial Site
City
Scarborough
State/Province
Ontario
Country
Canada
Facility Name
Clinical Trial Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Clinical Trial Site
City
Winnipeg
State/Province
Ontario
Country
Canada
Facility Name
Clinical Trial Site
City
Chicoutimi
State/Province
Quebec
Country
Canada
Facility Name
Clinical Trial Site
City
Lévis
State/Province
Quebec
Country
Canada
Facility Name
Clinical Trial Site
City
Pointe-Claire
State/Province
Quebec
Country
Canada
Facility Name
Clinical Trial Site
City
Québec
State/Province
Quebec
Country
Canada
Facility Name
Clinical Trial Site
City
Sherbrooke
State/Province
Quebec
Country
Canada
Facility Name
Clinical Trial Site
City
Trois-Rivières
State/Province
Quebec
Country
Canada
Facility Name
Clinical Trial Site
City
Victoriaville
State/Province
Quebec
Country
Canada
Facility Name
Clinical Trial Site
City
Québec
Country
Canada
Facility Name
Clinical Trial Site
City
Tallinn
Country
Estonia
Facility Name
Clinical Trial Site
City
Tallin
Country
Estonia
Facility Name
Clinical Trial Site
City
Tartu
Country
Estonia
Facility Name
Clinical Trial Site
City
Berlin
Country
Germany
Facility Name
Clinical Trial Site
City
Frankfurt
Country
Germany
Facility Name
Clinical Trial Site
City
Daugavpils
Country
Latvia
Facility Name
Clinical Trial Site
City
Kuldīga
Country
Latvia
Facility Name
Clinical Trial Site
City
Riga
Country
Latvia
Facility Name
Clinical Trial Site
City
Kaunas
Country
Lithuania
Facility Name
Clinical Trial Site
City
Panevėžys
Country
Lithuania
Facility Name
Clinical Trial Site
City
Vilnius
Country
Lithuania
Facility Name
Clinical Trial Site
City
Czestochowa
Country
Poland
Facility Name
Clinical Trial Site
City
Gdańsk
Country
Poland
Facility Name
Clinical Trial Site
City
Katowice
Country
Poland
Facility Name
Clinical Trial Site
City
Poznań
Country
Poland
Facility Name
Clinical Trial Site
City
Staszów
Country
Poland
Facility Name
Clinical Trial Site
City
Warszawa
Country
Poland
Facility Name
Clinical Trial Site
City
Wrocław
Country
Poland
Facility Name
Clinical Trial Site
City
Zamość
Country
Poland
Facility Name
Clinical Trial Site
City
Bayamón
Country
Puerto Rico
Facility Name
Clinical Trial Site
City
Chandler
ZIP/Postal Code
85224
Country
Puerto Rico
Facility Name
Clinical Trial Site
City
Manatí
Country
Puerto Rico
Facility Name
Clinical Trial Site
City
Ponce
Country
Puerto Rico
Facility Name
Clinical Trial Site
City
Carshalton
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Chelmsford
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Chorley
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Dundee
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Edinburgh
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Enfield
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Fowey
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Glasgow
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Hexham
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Lancashire Preston
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Leicestershire
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Leicester
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Liskeard
Country
United Kingdom
Facility Name
Clinical Trial Site
City
London
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Manchester
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Newquay
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Plymouth
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Sheffield
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Torpoint
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Wiltshire
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

We'll reach out to this number within 24 hrs